![Lixa](/sites/default/files/styles/medium/public/bn-di-company/lixa.png?itok=5Mqk26dm)
Lixa was established in 2021 with a focus on developing scalable antibiofilm technologies to treat antimicrobial resistance (AMR).
In 2022, Lixa won the Wesfarmers award for its Neo X platform technology at the WA Innovator of the Year Awards.
![]() |
NEWS: Tagged in Lixa assembles AMR avengers | 14 Feb 2025 |
![]() |
NEWS: Tagged in Appointments February 14, 2025 | 13 Feb 2025 |
![]() |
NEWS: Tagged in Lixa move NeoX-101 to clinical trials | 18 Nov 2024 |
![]() |
NEWS: Tagged in Bridging WA's Innovation to Commercialisation Gap | 09 Sep 2024 |
![]() |
NEWS: Tagged in Medtech startup Neurotologix wins WA Innovator of the Year | 05 Dec 2022 |
![]() |
NEWS: Tagged in Lixa targets global biotech market | 01 Sep 2022 |
![]() |
ADDED: Added to Startups list | 25 Aug 2022 |
![]() |
NEW ROLE: Andrew Barker, Chief Scientific Officer | 25 Aug 2022 |
![]() |
NEW ROLE: Craig Ridley, Director, Company Secretary, Chief Financial Officer | 25 Aug 2022 |
![]() |
NEW ROLE: Angela Fonceca, Co-Founder, Chief Operating Officer, Director | 25 Aug 2022 |